Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Eliana B Gomez"'
Autor:
Kelly D Sullivan, Hannah C Lewis, Amanda A Hill, Ahwan Pandey, Leisa P Jackson, Joseph M Cabral, Keith P Smith, L Alexander Liggett, Eliana B Gomez, Matthew D Galbraith, James DeGregori, Joaquín M Espinosa
Publikováno v:
eLife, Vol 5 (2016)
Although it is clear that trisomy 21 causes Down syndrome, the molecular events acting downstream of the trisomy remain ill defined. Using complementary genomics analyses, we identified the interferon pathway as the major signaling cascade consistent
Externí odkaz:
https://doaj.org/article/dcab55dc156745fda532a469ae3aaf67
Autor:
Eliana B Gomez, Kevin Ebata, Hetal S Randeria, Mary S Rosendahl, Ernst Peder Cedervall, Tony H Morales, Lauren M Hanson, Nicholas E Brown, Xueqian Gong, Jennifer Rachelle Stephens, Wenjuan Wu, Isabel Lippincott, Karin S. Ku, Richard A Walgren, Paolo B Abada, Joshua A Ballard, Charles K Allerston, Barbara J Brandhuber
Publikováno v:
Blood.
Bruton tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a major therapeutic target for B-cell driven malignancies. However, approved covalent BTK inhibitors (cBTKi) are associated with treatment limitations due to off-target side effects, sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db2333a010be3bb4fc08946997fe84cf
https://doi.org/10.1182/blood.2022018674
https://doi.org/10.1182/blood.2022018674
Autor:
Geoffrey R. Oxnard, Satoshi Yoda, Bruce G. Robinson, Eliana B. Gomez, Sarah-Jane Dawson, S. Michael Rothenberg, Justin F. Gainor, Dahlia Henry, Oliver Gautschi, Christine Khoo, Stephen Q. Wong, Edward Y. Zhu, Andrew T. Metcalf, Louis Stancato, Brian B. Tuch, Barbara J. Brandhuber, Steve Andrews, Jessica J. Lin, Lavinia Tan, Kevin Ronald Condroski, Vivek Subbiah, Lecia V. Sequist, Wayne Blosser, James F. Blake, Joshua Ballard, Kolakowski Gabrielle R, Kevin Ebata, Alexander Drilon, Benjamin Solomon, Michele Nguyen, Sebastian Hollizeck
Publikováno v:
Journal of Thoracic Oncology. 15:541-549
Introduction Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::742f3d3d111a3f191f93aa96d410395b
https://doi.org/10.1016/j.jtho.2020.01.006
https://doi.org/10.1016/j.jtho.2020.01.006
Autor:
Kevin Ronald Condroski, Kolakowski Gabrielle R, Thomas C. Irvin, Nisha A. Patel, Manoj Kumar, Joshua Ballard, Erin D. Anderson, Andrews Steven W, Eliana B. Gomez, Barbara J. Brandhuber, Faith D. Watson
Publikováno v:
Cancer Research. 81:1464-1464
In May 2020, selpercatinib became the first FDA-approved selective RET inhibitor, indicated for patients (pts) with RET fusion-positive NSCLC and thyroid cancer as well as RET-mutant medullary thyroid cancer. Despite the durable activity of selpercat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3835b3eb20997d91703b484b00e66cb
https://doi.org/10.1158/1538-7445.am2021-1464
https://doi.org/10.1158/1538-7445.am2021-1464
Publikováno v:
Blood. 136:32-33
Introduction: Bruton's Tyrosine Kinase (BTK) is an essential component of normal and malignant B-cell receptor signaling. Covalent BTK inhibitors have transformed the treatment of B-cell malignancies. Despite the marked efficacy of covalent BTKi, tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::734e28988bcc671a76166785f4be2f75
https://doi.org/10.1182/blood-2020-140581
https://doi.org/10.1182/blood-2020-140581
Autor:
Winnie I Nguy, Kevin Ebata, Barb J. Brandhuber, Stephen M. Rothenberg, Jennifer R. Brown, Stacey M. Fernandes, Aishath S Naeem, Eliana B. Gomez, Svitlana Tyekucheva, Vanessa Rai
Publikováno v:
Blood. 134:478-478
Clinical success with the targeted Bruton Tyrosine Kinase (BTK) inhibitors ibrutinib and acalabrutinib has greatly improved the outcome of patients with relapsed chronic lymphocytic leukemia (CLL). However toxic side effects and acquired resistance d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6555187c705733fa86c2bf33b42ced8
https://doi.org/10.1182/blood-2019-124362
https://doi.org/10.1182/blood-2019-124362
Autor:
Mary S. Rosendahal, Lippincott Isabel, Barb J. Brandhuber, Eliana B. Gomez, Andrews Steven W, Stephen M. Rothenberg
Publikováno v:
Blood. 134:4644-4644
Introduction: Bruton's Tyrosine Kinase (BTK) is an essential component of normal and malignant B-cell receptor signaling. Covalent BTK inhibitors have transformed the treatment of B-cell malignancies but are limited by off-target toxicity and acquire
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cdeef6638b71e75ad218de3c0303b330
https://doi.org/10.1182/blood-2019-126114
https://doi.org/10.1182/blood-2019-126114
Autor:
Steven G. Smith, Stacey Spencer, Barbara J. Brandhuber, S. Michael Rothenberg, Eliana B. Gomez, C. Todd Eary, Andrews Steven W
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:S216
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14cc32427bb5e3b97a747be4437000f2
https://doi.org/10.1016/j.clml.2018.07.081
https://doi.org/10.1016/j.clml.2018.07.081